In addition, they found that the intra-tumor application of the vaccine in a syngeneic mouse model with subcutaneous tumors not only delayed untreated transperitoneal tumors in a CD8 T cell-dependent manner but also delayed the growth of tumors. This evidence concerns the gene CD8A and neoplasm.